biotech investing Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines
biotech investing argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities
biotech investing argenx Presents Phase 3 ALKIVIA Data at ACR Convergence 2026 Showing Rapid and Sustained Improvement with Efgartigimod in Autoimmune Myositis
biotech investing argenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026
biotech investing argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
biotech investing argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
biotech investing argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease
biotech investing argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
biotech investing argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
biotech investing Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
biotech investing argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
biotech investing argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026
QIMC Extends DDH-26-05 Drilling to Beyond 1,000 Metres and Launches In-Situ Hydrogen Characterization and Extraction Program at Bennett Hill as Seismic Further Corroborates Two Distinct Hydrogen Systems in Nova Scotia
